tbuckley/cabot-search huggingface dataset:
Bullous Eruption in Lupus Erythematosus
Authors: JAMES P. MANNION
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 February 1983Bullous Eruption in Lupus ErythematosusJAMES P. MANNION, M.D.JAMES P. MANNION, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-2-261_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: I note that Hall and associates (1) fail to consider porphyria cutanea tarda as a diagnosis (2). Lupus erythematosus, either discoid or systemic, and porphyria cutanea tarda may co-exist, and either may present with photosensitivity. The description of the skin changes in all four patients seemed compatable with porphyria cutanea tarda. All four patients had been taking antimalaria drugs, which have been known to unmask porphyria cutanea tarda. For this reason, urinary porphyrins should be measured before antimalarial therapy in any case of lupus erythematosus, and I suggest this for the authors' consideration....References1. HALL R, LAWLEY T, SMITH H, and KATZ S. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med. 1982;97:165-70. LinkGoogle Scholar2. GROSSMAN M. Porphyria cutanea tarda. Med Clin North Am. 1980;807. CrossrefMedlineGoogle Scholar1. HALL R, LAWLEY T, SMITH H, and KATZ S. Bulbus eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med. 1982;97:165-70. LinkGoogle Scholar2. KATZ S and MARKS J. Dermatitis herpetiformis. In: FITZPATRICK TB, EISEN AZ, WOLFF K, FREEDBERG IM, AUSTEN KF, eds. Dermatology in General Medicine. New York: McGraw-Hill, Inc.; 1979:326-30. Google Scholar3. PENNEYS N and WILEY H. Herpetiform blisters in systemic lupus erythematosus. Arch Dermatol. 1979;115:1427-8. CrossrefMedlineGoogle Scholar4. DAVIES M, MARKS R, and WADDINGTON E. Simultaneous systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol. 1976;112:1292-4. CrossrefMedlineGoogle Scholar5. ARONSON A, SOLTANI K, ARONSON I, and ONG R. Systemic lupus erythematosus and dermatitis herpetiformis: concurrence with Marian's syndrome. Arch Dermatol. 1979;115:68-70. CrossrefMedlineGoogle Scholar6. MONCADA B. Dermatitis herpetiformis in association with systemic lupus erythematosus. Arch Dermatol. 1974;109:723-5. CrossrefMedlineGoogle Scholar1. KATZ S, HALL R, LAWLEY T, and STROBER W. Dermatitis herpetiformis: the skin and the gut. Ann Intern Med. 1980;93:857-74. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JAMES P. MANNION, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 February 1983Volume 98, Issue 2Page: 261-261KeywordsAntimalarialsDrugsLupus erythematosusPorphyriaPorphyrins ePublished: 1 December 2008 Issue Published: 1 February 1983 PDF downloadLoading ...
Antibody Response to Influenza Vaccination in Renal Transplant Patients
Authors: RUFINO C. PABICO
Journal: Annals of Internal Medicine (1976)

Thirty renal transplant recipients received 0.5 ml of Influenza Virus Vaccine, Bivalent, USP, intramuscularly. Serum hemagglutination-inhibiting and nasal secretory neutralizing antibodies were measured before and 3 to 4 weeks after vaccination. Creatinine clearance and urinary protein excretion were measured before and weekly for 4 to 8 weeks after vaccination. Ten of 13 patients (77%) with creatinine clearance of greater than or equal to 70 ml/min-1.73m2 (group I) had greater than or equal to a fourfold increase in hemagglutination-inhibiting antibody titers to influenza A or B virus after vaccination, while only six of 17 patients (35%) with creatinine clearance of greater than 70 ml/min-1.73m2 (group II) had a similar increase (chi-square = 5.129; P less than 0.05). Six of 13 patients (46%) in group I had greater than or equal to a fourfold increase in neutralizing antibody titers to influenza A or B virus after vaccination, whereas none in group II had a similar increase (chi-square = 7.135; P less than 0.01). There were no adverse effects on the allografts. Only minor side effects were noted in a few patients. Because of its safety and antigenicity, influenza vaccination should be offered to renal transplant recipients particularly during threats of epidemic outbreaks.
PUVA treatment of psoriasis in Italy
Authors: P.G. Calzavara-Pinton, M. Rastrelli, A. Carlino, F.De Costanza, C. Varotti, G.De Panfilis
Journal: British Journal of Dermatology (1992)

Journal Article PUVA treatment of psoriasis in Italy Get access P.G. Calzavara‐Pinton, P.G. Calzavara‐Pinton Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, Italy Search for other works by this author on: Oxford Academic Google Scholar M. Rastrelli, M. Rastrelli Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, Italy Search for other works by this author on: Oxford Academic Google Scholar A. Carlino, A. Carlino Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, Italy Search for other works by this author on: Oxford Academic Google Scholar F.De Costanza, F.De Costanza Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, Italy Search for other works by this author on: Oxford Academic Google Scholar C. Varotti, C. Varotti Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, ItalyDepartment of Dermatology, Bologna University, Bologna, Italy Search for other works by this author on: Oxford Academic Google Scholar G.De Panfilis G.De Panfilis Department of Dermatology, Brescia University Hospital, p.le Spedali Civili 1, 1‐25125 Brescia, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 127, Issue 5, 1 November 1992, Page 548, https://doi.org/10.1111/j.1365-2133.1992.tb14863.x Published: 01 November 1992
Diastolic-systolic coronary flow differences are caused by intramyocardial pump action in the anesthetized dog.
Authors: J A Spaan, N P Breuls, J D Laird
Journal: Circulation Research (1981)

The effect of cardiac contraction on coronary arterial flow has been described in terms of an intramyocardiaJ pump, which displaces blood backward and forward during systole and diastole, respectively.Normally, the mean forward flow exceeds, and consequently conceals, this backflow.The main left coronary artery of six anesthetized open-chest dogs was perfused with a Gregg cannula from a constant pressure source via a pcrfusion line containing an adjustable stenosis.At mean left main arterial pressures, P^, of 65, 90, 125, and 155 mm Hg, the hearts were perfused via different grades of stenosis, while a constant mean perfusion pressure (Pu,) distal to the stenosis was maintained.Mean coronary flow was then independent of stenosis grade.However, with increasing stenosis grade, the systolic-diastolic coronary flow difference decreased, whereas the dlastolic-systolic coronary pressure difference increased.By varying the stenosis grade at constant P^ linear relationships between diastolic-systolic pressure difference and flow difference were obtained and were interpreted as being a result of an electrical analog potential-source equivalent.From the potential-source equivalent, the diastolic-systolic pressure changes of the intramyocadial pump, pi_, can be determined as well as the coronary resistance, R., impeding the flow variations originated by p^.We found p^ = 53.1 ± 7.02 (SD) nun Hg, and independent of P^.R. was correlated with the resistance to coronary flow, Re, via R. = 0.63 x R,. -12.9 mm Hg»s/ml (r -0.939, n -25).R* was defined as (Pic -14 nun Hg)/mean coronary flow.The waterfall model extended to allow for autoregulation to achieve an equal division of mean flow over the myocardium could not explain these results.From a decay curve of coronary arterial pressure following clamping of the perfusion line, intramyocardial coronary capacitance was estimated to be approximately 0.07 ml/mm rig/100 g LV.This value is in agreement with published volume pressure relationships of the intramyocardial blood compartment.The phasic coronary blood flow component requires intramyocardial arterial volume.We conclude that systolic-diastolic variations in coronary blood flow are not due to varying resistances but are caused by an active intramyocardial pump.
111 Liver transplantation from donors aged 80 years and over: Pushing the limit
Authors: P. Caraceni, B. Nardo, R. Montalti, M. Masetti, L. Urbani, P. Beltempo, R. Bertelli, L. Puviani, M. Bernardi, F. Filipponi, A. Pinna, A. Cavallari
Journal: Journal of Hepatology (2004)
Henry William Bunje
Authors: Griff Owen
Journal: BMJ (2005)

​FormerFormer principal medical officer Medical Research Council, London (b Hong Kong 1921; q St Bartholomew's Hospital, London, 1944; MD, FRCP), died from multiple myelomatosis and pneumonia on 12 August 2005.




Figure 1




After resident appointments, national service in the Royal Air Force, and further posts in internal medicine at Barts, Henry spent three years at the University of the West Indies, Jamaica, followed by a year at Bellevue Hospital, New York. He returned to the United Kingdom in 1957 to join the Medical Research Council, first as a member of the scientific staff, transferring two years later to the medical division at head office. Henry was a man of great personal charm, and of elegant appearance and immaculate dress, almost invariably with a bow tie and a rose in the lapel. He leaves a wife, Elizabeth, and three children.
Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2–Targeted Therapies for Breast Cancer
Authors: Daniel J. Zabransky, Ben Ho Park
Journal: Journal of Clinical Oncology (2014)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2013.53.5070 Journal of Clinical Oncology - published online before print March 3, 2014 PMID: 24590645 Estrogen Receptor and Receptor Tyrosine Kinase Signaling: Use of Combinatorial Hormone and Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2–Targeted Therapies for Breast Cancer Daniel J. ZabranskyxDaniel J. ZabranskySearch for articles by this author , Ben Ho ParkxBen Ho ParkSearch for articles by this author Show More Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD https://doi.org/10.1200/JCO.2013.53.5070 First Page Full Text PDF Figures and Tables © 2014 by American Society of Clinical Oncology
Effects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity. Implications in neuronal injury.
Authors: C C Chao, S Hu, M Tsang, J Weatherbee, T W Molitor, W R Anderson, P K Peterson
Journal: Journal of Clinical Investigation (1992)

Cytokines have been implicated in the pathogenesis of a number of brain diseases in which neurological dysfunction has been attributed to a change in amino acid neurotransmitter metabolism. In the present in vitro study, we investigated the effects of cytokines on astrocyte glutamine synthetase (GS) activity and subsequently on N-methyl-D-aspartate (NMDA) receptor-mediated neurotoxicity. Proinflammatory cytokines IL-1 alpha, IL-1 beta, and IL-6 at a concentration of 20 ng/ml did not affect GS activity; however, tumor necrosis factor-alpha inhibited this activity by 20% in mixed neuronal/astrocyte cultures. Treatment for 24 h with transforming growth factor (TGF)-beta 1 or -beta 2 inhibited up to 60% GS activity. TGF-beta 2 also inhibited GS in enriched astrocyte cultures with an ED50 of 10 pg/ml. Antibodies specific to TGF-beta 2 blocked this effect. Treatment of astrocytes with TGF-beta 2 (250 pg/ml) resulted in markedly dilated rough endoplasmic reticulum. Since astrocyte GS may play a protective role in NMDA receptor-mediated neurotoxicity, we treated mixed neuronal/astrocyte cultures with TGF-beta 2 (250 pg/ml) and found a threefold potentiation of NMDA receptor-mediated neurotoxicity. These data suggest that TGF-beta impairs astrocyte GS function and enhances neurotoxicity, thus providing insight into understanding one mechanism of cytokine-mediated central nervous system disease.
Neuropathies and Myopathies Associated With Occult Malignancies
Authors: Max Karl Newman, Robert J. Gugino
Journal: JAMA (1964)

Weakness of the legs in the aged is often a manifestation of hidden malignancy. Sensory and motor nerve conduction studies were undertaken of 100 patients over the age of 65 who were undergoing pathologic neuromusculoskeletal changes. These changes, which antedate the primary malignant focus, may be subacute cerebellar degeneration, sensory neuropathy, myopathic alterations, myasthenic states, polymyositis and pathologic collagen-like changes, and multiple combinations of motor neuron disease. Clinical observations supplemented by electromyography, motor and sensory nerve conduction studies, and muscle studies made possible an objective, early, exact diagnosis of occult malignancy in eight patients.
Suppressibility of Thyroid Function Despite High Levels of Long-Acting Thyroid Stimulator
Authors: EDWARD T. WONG
Journal: Annals of Internal Medicine (1972)

The long-acting thyroid stimulator (LATS) has been said to be the pathogenetic factor of the thyroid autonomy or hyperfunction in Graves' disease. Two patients had the ophthalmopathy and pretibial myxedema of Graves' disease occurring with Hashimoto's thyroiditis. Both patients had suppressed thyroid function in response to exogenous thyroid hormone in spite of the presence of high levels of LATS in their serums. The long-acting thyroid stimulator may not be the cause of the fixed thyroid function of Graves' disease.
The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1 antitrypsin-elastase complexes and amyloid-beta peptide.
Authors: G Joslin, G L Griffin, A M August, S Adams, R J Fallon, R M Senior, D H Perlmutter
Journal: Journal of Clinical Investigation (1992)

The serpin-enzyme complex (SEC) receptor mediates catabolism of alpha 1-antitrypsin (alpha 1-AT)-elastase complexes and increases in synthesis of alpha 1-AT in cell culture. The SEC receptor recognizes a pentapeptide domain on alpha 1-AT-elastase complexes (alpha 1-AT 370-374), and the same domain in several other serpins, amyloid-beta peptide, substance P, and other tachykinins. Thus, it has also been implicated in the biological properties of these ligands, including the neurotoxic effect of amyloid-beta peptide. In this study, we examined the possibility that the SEC receptor mediates the previously described neutrophil chemotactic activity of alpha 1-AT-elastase complexes, and whether the other ligands for the SEC receptor have neutrophil chemotactic activity. The results show that 125I-peptide 105Y (based on alpha 1-AT 359-374) binds specifically and saturably to human neutrophils, and the characteristics of this binding are almost identical to that of monocytes and hepatoma-derived hepatocytes. Peptide 105Y and amyloid-beta peptide mediate chemotaxis for neutrophils with maximal stimulation at 1-10 nM. Mutant or deleted forms of peptide 105Y, which do not bind to the SEC receptor, have no effect. The neutrophil chemotactic effect of alpha 1-AT-elastase complexes is blocked by antiserum to peptide 105Y and by antiserum to the SEC receptor, but not by control antiserum. Preincubation of neutrophils with peptide 105Y or substance P completely blocks the chemotactic activity of amyloid-beta peptide, but not that of FMLP. These results, therefore, indicate that the SEC receptor can be modulated by homologous desensitization and raise the possibility that pharmacological manipulation of this receptor will modify the local tissue response to inflammation/injury and the neuropathologic reaction of Alzheimer's disease.
Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles.
Authors: R F Kauffman, B G Utterback, D W Robertson
Journal: Circulation Research (1989)

LY186126 was found to be a potent inhibitor of type IV cyclic AMP phosphodiesterase located in the sarcoplasmic reticulum of canine cardiac muscle. This compound, a close structural analogue of indolidan (LY195115), was prepared in high specific activity, tritiated form to study the positive inotropic receptor(s) for cardiotonic phosphodiesterase inhibitors such as indolidan and milrinone. A high-affinity binding site for [3H]LY186126 was observed (Kd = 4 nM) in purified preparations of canine cardiac sarcoplasmic reticulum vesicles. Binding was proportional to vesicle protein, was inactivated by subjecting membranes to proteolysis or boiling, and was dependent on added Mg2+. Scatchard analysis suggested the presence of a single class of binding sites in the membrane preparation. Indolidan, milrinone, and LY186126 (all at 1 microM) produced essentially complete displacement of bound [3H]LY186126, while nifedipine, propranolol, and prazosin had little or no effect at this concentration. This represents the first reported use of a radioactive analogue to label the inotropic receptor for cardiotonic phosphodiesterase inhibitors. The results suggest that [3H]LY186126 is a useful radioligand for examining the subcellular site(s) responsible for positive inotropic effects of these drugs.
Legal and Medical Death — Kansas Takes the First Step
Authors: William J. Curran
Journal: New England Journal of Medicine (1971)

Come away, come away, death And in sad cypress let me be laid;Fly away, fly away, breath; I am slain by a fair cruel maid.My shroud of white, stuck all with yew, O prepare it!My part of death, no one so true Did share it.SHAKESPEARE said it well: no one else shares in a person's death. Yet we all prepare for it and the living "pronounce" the death of the individual. The Bard spoke of death as the the flight of breath. In a medical sense it has been defined in the past as the cessation . . .
The Acute Abdomen
Authors: Yolanda Adler
Journal: JAMA (1974)

This book is compiled from two issues of<i>Seminars in Roentgenology</i>on the subject of the acute abdomen. Eighteen authors have collaborated in 13 chapters that present different aspects of the radiological approach to this subject. The first chapter deals with the technical aspects of the examination, a systematic review of the ways and means available to the radiologist, and contains an excellent description of the details of technique. It is followed by a series of chapters that discuss intestinal obstruction, the special problems in pediatric cases, and inflammatory diseases. Acute extraperitoneal infection is described in an extremely informative chapter, with superb anatomical descriptions. Toxic megacolon is decribed concisely and to the point, and the roentgenological findings of diverticulitis are well analyzed and correlated with their pathological base. The radiologically difficult subject of acute pancreatitis is thoroughly reviewed and there is an excellent discussion about the diagnosis of hepatobiliary disease.
The molecular signature of MDS stem cells supports a stem-cell origin of 5q− myelodysplastic syndromes
Authors: Lars Nilsson, Patrik Edén, Eleonor Olsson, Robert Månsson, Ingbritt Åstrand-Grundström, Bodil Strömbeck, Kim Theilgaard-Mönch, Kristina Anderson, Robert Hast, Eva Hellström-Lindberg, Jan Samuelsson, Gösta Bergh, Claus Nerlov, Bertil Johansson, Mikael Sigvardsson, Åke Borg, Sten Eirik W. Jacobsen
Journal: Blood (2007)
Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity
Authors: Hee Kyung Ahn, Jun Ho Jang, Kihyun Kim, Hee‐Jin Kim, Sun‐Hee Kim, Chul Won Jung, Dong Hwan (Dennis) Kim
Journal: American Journal of Hematology (2011)

Monosomal karyotype (MK) reflects highly unfavorable prognosis in patients with acute myeloid leukemia (AML). This study aimed to study the association of AML-MK with multidrug resistance (MDR) functional activity. A total of 369 AML patients (excluding APL) between 1995 and 2008 at a single center were included retrospectively. Functional MDR activity was evaluated with rhodamine-123 efflux activity with/without verapamil inhibition. MK was noted in 23 patients, only among whom classified into unfavorable cytogenetic risk group. Unfavorable cytogenetic subgroup with MK showed shorter OS (8.7 ± 5.9% vs. 23.5 ± 7.5% at 3 years, P = 0.030), EFS (8.7 ± 5.9% vs. 19.0 ± 6.9% at 3 years, P = 0.029), and a lower CR rate (34.8% vs. 65.7%, P = 0.031) compared with unfavorable subgroup without MK. Functional MDR activity was significantly higher in the unfavorable cytogenetic group with MK compared to all other cytogenetic risk groups taken as a whole (P = 0.026) and showed a trend toward statistical significance when compared with the unfavorable cytogenetic risk group without MK (P = 0.06). AML patients harboring MK showed a poor outcome in terms of lower CR rate and worse EFS/OS, and the presence of MK appeared to be associated with higher MDR functional activity of leukemic blasts.
Aromatase inhibitors and inactivators in breast cancer
Authors: P. E. Lonning
Journal: BMJ (2001)

Breast cancer is the commonest malignant disease among Western women, and, although overall survival has improved with earlier diagnosis by mammography and with adjuvant therapy, it still represents a leading cause of cancer related death. Endocrine treatment is recommended as first line therapy in patients with hormone sensitive tumours (oestrogen and progesterone receptor positive) as most forms of endocrine treatment cause fewer side effects than chemotherapy. No curative treatment is currently available for patients with distant metastases, and the goal of therapy is palliative. This stresses the need for treatments with low toxicity.

Aromatase inhibitors and inactivators are drugs that suppress oestrogen production in postmenopausal women through inhibition of the final step in their synthesis, conversion of androgens to oestrogens. While oestrogen synthesis in the ovary ceases at the menopause, oestrogens are still produced in different peripheral tissues, including benign and malignant breast tissue. Aromatase inhibitors are non-steroidal …